FDA approves Gimoti for diabetic gastroparesis

Evoke Pharma announced in a press release that the FDA has approved the new drug application for Gimoti nasal spray to relieve symptoms in adults with acute and recurrent diabetic gastroparesis.“We are extremely pleased to have received FDA approval to commercially market Gimoti [metoclopramide, Evoke Pharma] in the United States,” David Gonyer, R.Ph, president and CEO, said in the release. “This approval represents the first novel pharmaceutical treatment for gastroparesis in several decades. Many times, patients do not experience adequate relief of their gastroparesisRead More

Share on facebook
Share on twitter
Share on linkedin